Literature DB >> 3047654

Central nervous system leukemia.

W A Bleyer1.   

Abstract

With one exception, the risk and severity of neurotoxicity is directly proportional to the number of therapeutic modalities used. Three are worse than two, and two are worse than one. Combinations of therapeutic modalities which include CNS RT appear to be the most neurotoxic. The least neurotoxic combination of two modalities appears to be the IT MTX with high-dose intravenous MTX. Thus far, high-dose MTX appear to be the safest single modality, in terms of acute, subacute, and delayed neurotoxicity. The improved outcome in intellectual and academic performance in the NCI-191/CCG-134P conjoint trial of the CCSG and the Pediatric Branch described above (see section of Presymptomatic CNS Therapy) appears to confirm this observation. Whether triple IT chemotherapy will have the same result remains to be established. If CNS RT must be combined with MTX therapy, the least neurotoxic approach appears to be to administer these modalities in sequence, IT MTX, or high-dose intravenous MTX followed by CNS RT. MTX given during or after CNS RT appears from the clinical data to be more likely to produce severe neurologic sequelae. An ultimate goal would be to avoid both ionizing RT and IT chemotherapy. To this end, the NCI/CCSG study has demonstrated that this may be possible, except for those patients who are at the highest risk for CNS relapse despite conventional CNS prophylaxis. Meanwhile, for presymptomatic therapy, either cranial RT (18 Gy total dose at 120-180 cGy per day) in conjunction with IT MTX, or frequent IT chemotherapy with MTX, cytarabine, and hydrocortisone combined and administered throughout induction, consolidation, and maintenance is eminently justified in the majority of children with ALL. On a worldwide basis, chemoradiotherapy with cranial RT and IT MTX remains the established method of preventing overt CNS leukemia. The benefits of this intervention, in terms of prevention of symptomatic CNS leukemia, prolongation of complete remission, and increased cure rates, are clearly worth the risks.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3047654     DOI: 10.1016/s0031-3955(16)36510-5

Source DB:  PubMed          Journal:  Pediatr Clin North Am        ISSN: 0031-3955            Impact factor:   3.278


  11 in total

Review 1.  Extramedullary manifestations in acute lymphoblastic leukemia in children: a systematic review and guideline-based approach of treatment.

Authors:  Mahdi Shahriari; Nader Shakibazad; Sezaneh Haghpanah; Khadijeh Ghasemi
Journal:  Am J Blood Res       Date:  2020-12-15

2.  Detection of minimal leukemic cells in cerebral spinal fluid of children with acute lymphoblastic leukemia using the polymerase chain reaction technique.

Authors:  X Li; A Yang; H Fei
Journal:  J Tongji Med Univ       Date:  1998

3.  Unusual seizures with a benign course in a case of acute lymphoblastic leukemia of childhood.

Authors:  E Del Giudice; P Ruosi; A Fiorillo; A Iovine; S Striano
Journal:  Ital J Neurol Sci       Date:  1993-06

Review 4.  Transient focal leukoencephalopathy following intraventricular methotrexate and cytarabine. A complication of the Ommaya reservoir: case report and review of the literature.

Authors:  V Colamaria; R Caraballo; C Borgna-Pignatti; P Marradi; R Balter; C Mazza; C Procacci; B Dalla Bernardina
Journal:  Childs Nerv Syst       Date:  1990-06       Impact factor: 1.475

5.  Intracerebral (parenchymal) infusion of methotrexate: report of a case.

Authors:  K A Page; H Vogel; D S Horoupian
Journal:  J Neurooncol       Date:  1992-02       Impact factor: 4.130

6.  Tumefactive intracranial presentation of precursor B-cell acute lymphoblastic leukemia.

Authors:  Craig M Forester; Chi L Braunreiter; Hasan Yaish; Gary L Hedlund; Zeinab Afify
Journal:  Pediatr Radiol       Date:  2009-09-10

7.  Prognostic importance of ophthalmic manifestations in childhood leukaemia.

Authors:  K Ohkoshi; W G Tsiaras
Journal:  Br J Ophthalmol       Date:  1992-11       Impact factor: 4.638

8.  Microprocessor in controlled transdermal drug delivery of anti-cancer drugs.

Authors:  N S Chandrashekar; R H Shobha Rani
Journal:  J Mater Sci Mater Med       Date:  2008-07-01       Impact factor: 3.896

9.  PET-CT in detection of meningeal metastasis in neuroblastoma.

Authors:  Madhavi Chawla; Ramamohan Reddy; Rajender Kumar; Chandan J Das; Sandeep Agarwala; Amar M Tiwari; Arun Malhotra; Rakesh Kumar
Journal:  Pediatr Surg Int       Date:  2009-01-08       Impact factor: 1.827

10.  MR imaging of the brain in patients cured of acute lymphoblastic leukemia--the value of gradient echo imaging.

Authors:  M S M Chan; D J Roebuck; M-P Yuen; C-K Li; Y-L Chan
Journal:  AJNR Am J Neuroradiol       Date:  2006-03       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.